Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 18, Issue 2
15 January 2012
Issue Cover
All Issues
  • Cover Image

    Cover Image

    issue cover
    Although antiangiogenic therapies are effective and comparatively safe treatments against human cancer, renal toxicity is one of the major concerns. Anti-VEGFR2 immunoliposomes loaded with a chemotherapeutic drug showed marked antitumor activity in various tumor models. Importantly, no long-term renal side effects were evident with this therapy. This image shows a section of mouse kidneys 18 months after repeated injection of anti-VEGFR2 immunoliposomes loaded with doxorubicin. For details, see the article by Wicki and colleagues on page 454 of this issue.
  • PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265

Highlights

Highlights of This Issue
View articletitled, Highlights of This Issue
Open the PDF for in another window

CCR Translations

BAP1tism of a Tumor Suppressor
Scott E. Woodman
View articletitled, BAP1tism of a Tumor Suppressor
Supplementary data
Open the PDF for in another window

Molecular Pathways

Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis
William C. Dougall
View articletitled, Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis
Open the PDF for in another window

Perspective

New Challenges in Endpoints for Drug Development in Advanced Melanoma
Antoni Ribas; Peter Hersey; Mark R. Middleton; Helen Gogas; Keith T. Flaherty; Vernon K. Sondak; John M. Kirkwood
View articletitled, New Challenges in Endpoints for Drug Development in Advanced Melanoma
Open the PDF for in another window

Review

Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects
Michaela R. Reagan; Irene M. Ghobrial
View articletitled, Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects
Open the PDF for in another window

Human Cancer Biology

Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution
Brooke E. Sylvester; Dezheng Huo; Andrey Khramtsov; Jing Zhang; Rana V. Smalling; Sope Olugbile; Blase N. Polite; Olufunmilayo I. Olopade
View articletitled, Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution
Supplementary data
Open the PDF for in another window
A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
Rajasubramaniam Shanmugam; Padmaja Gade; Annique Wilson-Weekes; Hamid Sayar; Attaya Suvannasankha; Chirayu Goswami; Lang Li; Sushil Gupta; Angelo A. Cardoso; Tareq Al Baghdadi; Katie J. Sargent; Larry D. Cripe; Dhananjaya V. Kalvakolanu; H. Scott Boswell
View articletitled, A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses <em>DAPK1</em> in Acute Myeloid Leukemia
Supplementary data
Open the PDF for in another window
Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome
Rossitza Lazova; Robert L. Camp; Vincent Klump; Summar F. Siddiqui; Ravi K. Amaravadi; John M. Pawelek
View articletitled, Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome
Supplementary data
Open the PDF for in another window
Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Hiu-Fung Yuen; Ka-Kui Chan; Claire Grills; James T. Murray; Angela Platt-Higgins; Osama Sharaf Eldin; Ken O'Byrne; Pasi Janne; Dean A. Fennell; Patrick G. Johnston; Philip S. Rudland; Mohamed El-Tanani
View articletitled, Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Supplementary data
Open the PDF for in another window
Serum Interleukin-6, Insulin, and HOMA-IR in Male Individuals with Colorectal Adenoma
Yu Sasaki; Hiroaki Takeda; Takeshi Sato; Tomohiko Orii; Shoichi Nishise; Ko Nagino; Daisuke Iwano; Takao Yaoita; Kazuya Yoshizawa; Hideki Saito; Yasuhisa Tanaka; Sumio Kawata
View articletitled, Serum Interleukin-6, Insulin, and HOMA-IR in Male Individuals with Colorectal Adenoma
Open the PDF for in another window
Lifetime Cancer Risks in Individuals with Germline PTEN Mutations
Min-Han Tan; Jessica L. Mester; Joanne Ngeow; Lisa A. Rybicki; Mohammed S. Orloff; Charis Eng
View articletitled, Lifetime Cancer Risks in Individuals with Germline <em>PTEN</em> Mutations
Open the PDF for in another window

Cancer Therapy: Preclinical

Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Solange Landreville; Olga A. Agapova; Katie A. Matatall; Zachary T. Kneass; Michael D. Onken; Ryan S. Lee; Anne M. Bowcock; J. William Harbour
View articletitled, Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Supplementary data
Open the PDF for in another window
Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells
Sascha Dietrich; Oliver H. Krämer; Esther Hahn; Claudia Schäfer; Thomas Giese; Michael Hess; Theresa Tretter; Michael Rieger; Jennifer Hüllein; Thorsten Zenz; Anthony D. Ho; Peter Dreger; Thomas Luft
View articletitled, Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells
Open the PDF for in another window
Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma
Jens H.W. Pahl; S. Eriaty N. Ruslan; Emilie P. Buddingh; Susy J. Santos; Karoly Szuhai; Massimo Serra; Hans Gelderblom; Pancras C.W. Hogendoorn; R. Maarten Egeler; Marco W. Schilham; Arjan C. Lankester
View articletitled, Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma
Open the PDF for in another window
Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer
Audrey Cras; Béatrice Politis; Nicole Balitrand; Diane Darsin-Bettinger; Pierre Yves Boelle; Bruno Cassinat; Marie-Elisabeth Toubert; Christine Chomienne
View articletitled, Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer
Supplementary data
Open the PDF for in another window
Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth
Andreas Wicki; Christoph Rochlitz; Annette Orleth; Reto Ritschard; Imke Albrecht; Richard Herrmann; Gerhard Christofori; Christoph Mamot
View articletitled, Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth
Supplementary data
Open the PDF for in another window
EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
Michele Cioffi; Jorge Dorado; Patrick A. Baeuerle; Christopher Heeschen
View articletitled, EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
Supplementary data
Open the PDF for in another window
CPTH6, a Thiazole Derivative, Induces Histone Hypoacetylation and Apoptosis in Human Leukemia Cells
Daniela Trisciuoglio; Ylenia Ragazzoni; Andrea Pelosi; Marianna Desideri; Simone Carradori; Chiara Gabellini; Giovanna Maresca; Riccardo Nescatelli; Daniela Secci; Adriana Bolasco; Bruna Bizzarri; Chiara Cavaliere; Igea D'Agnano; Patrizia Filetici; Lucia Ricci-Vitiani; Maria Giulia Rizzo; Donatella Del Bufalo
View articletitled, CPTH6, a Thiazole Derivative, Induces Histone Hypoacetylation and Apoptosis in Human Leukemia Cells
Supplementary data
Open the PDF for in another window
Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia
Jacqueline M. Tromp; Christian R. Geest; Esther C.W. Breij; Judith A. Elias; Jacoline van Laar; Dieuwertje M. Luijks; Arnon P. Kater; Tim Beaumont; Marinus H.J. van Oers; Eric Eldering
View articletitled, Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia
Supplementary data
Open the PDF for in another window
VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Hailing Lu; Gregory N. Dietsch; Maura-Ann H. Matthews; Yi Yang; Smita Ghanekar; Margaret Inokuma; Maria Suni; Vernon C. Maino; Katherine E. Henderson; James Jeffry Howbert; Mary L. Disis; Robert M. Hershberg
View articletitled, VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Supplementary data
Open the PDF for in another window
Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
Xuesong Liu; Yan Shi; David X. Maag; Joann P. Palma; Melanie J. Patterson; Paul A. Ellis; Bruce W. Surber; Damien B. Ready; Niru B. Soni; Uri S. Ladror; Allison J. Xu; Ramesh Iyer; John E. Harlan; Larry R. Solomon; Cherrie K. Donawho; Thomas D. Penning; Eric F. Johnson; Alexander R. Shoemaker
View articletitled, Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a <em>Bona Fide</em> PARP Inhibitor
Open the PDF for in another window

Imaging, Diagnosis, Prognosis

Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer
Jih-Hsiang Lee; Elisa Giovannetti; Jin-Hyeok Hwang; Iacopo Petrini; Qiuyan Wang; Johannes Voortman; Yonghong Wang; Seth M. Steinberg; Niccola Funel; Paul S. Meltzer; Yisong Wang; Giuseppe Giaccone
View articletitled, Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer
Supplementary data
Open the PDF for in another window
MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Nigel B. Jamieson; Douglas C. Morran; Jennifer P. Morton; Asif Ali; Euan J. Dickson; C. Ross Carter; Owen J. Sansom; T.R. Jeffry Evans; Colin J. McKay; Karin A. Oien
View articletitled, MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Supplementary data
Open the PDF for in another window
Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas
Harry H. Yoon; Qian Shi; William R. Sukov; Anne E. Wiktor; Maliha Khan; Christopher A. Sattler; Axel Grothey; Tsung-Teh Wu; Robert B. Diasio; Robert B. Jenkins; Frank A. Sinicrope
View articletitled, Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas
Supplementary data
Open the PDF for in another window

Cancer Therapy: Clinical

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
John M. Kirkwood; Lars Bastholt; Caroline Robert; Jeff Sosman; James Larkin; Peter Hersey; Mark Middleton; Mireille Cantarini; Victoria Zazulina; Karin Kemsley; Reinhard Dummer
View articletitled, Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
Supplementary data
Open the PDF for in another window
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty; Patricia M. LoRusso; Angela DeMichele; Vandana G. Abramson; Rachel Courtney; Sophia S. Randolph; M. Naveed Shaik; Keith D. Wilner; Peter J. O'Dwyer; Gary K. Schwartz
View articletitled, Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Supplementary data
Open the PDF for in another window

Predictive Biomarkers and Personalized Medicine

A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303
Federico Innocenti; Kouros Owzar; Nancy L. Cox; Patrick Evans; Michiaki Kubo; Hitoshi Zembutsu; Chen Jiang; Donna Hollis; Taisei Mushiroda; Liang Li; Paula Friedman; Liewei Wang; Dylan Glubb; Herbert Hurwitz; Kathleen M. Giacomini; Howard L. McLeod; Richard M. Goldberg; Richard L. Schilsky; Hedy L. Kindler; Yusuke Nakamura; Mark J. Ratain
View articletitled, A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303
Supplementary data
Open the PDF for in another window
Genetic Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or II Non–Small Cell Lung Cancer Patients
Klaus W. Wagner; Yuanqing Ye; Jie Lin; Ara A. Vaporciyan; Jack A. Roth; Xifeng Wu
View articletitled, Genetic Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or II Non–Small Cell Lung Cancer Patients
Open the PDF for in another window

Advertisement

Breaking
Federal Health Officials Told to Freeze Public Communications
FDA Approves Drugs for MCL, Colorectal and Breast Cancers
NCI, NIH Directors Stepping Down
View more recent articles
Latest News
Genome Editing Sheds Light on BRCA2 Mutations
Wildfires Spare Los Angeles Area Cancer Centers—For Now
Structural Variants Increase Risk of Pediatric Cancers
View more recent articles
Research Watch
AI Models Can Effectively Detect Ovarian Cancer from Ultrasound Images
Bile Acids Modulate T-cell Response and Function in Liver Cancer
The Zinc-Binding Cysteine Proteome Comprises Targetable Cancer Vulnerabilities
View more recent articles

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.

  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2025 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept